


For patients at risk of febrile neutropenia¹

Reimagining the pegfilgrastim experience



Stimufend[®]
pegfilgrastim-fpgk



Important Safety Information

Indications and Usage

Stimufend is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Stimufend is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Limitations of Use

Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Contraindication

- Stimufend (pegfilgrastim-fpgk) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
- Reactions have included anaphylaxis

Please see additional Important Safety Information on pages 18-19 and accompanying Full Prescribing Information.




**FRESENIUS
KABI**

For patients at risk of febrile neutropenia¹

Reimagining the pegfilgrastim experience



StimuFend[®]
pegfilgrastim-fpgk



Important Safety Information (cont'd)

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
- Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain

Please see additional Important Safety Information on pages 18-19 and accompanying Full Prescribing Information.

A continuum of support lets you focus on the battle against cancer

- Clinically proven biosimilarity to Neulasta[®] (pegfilgrastim)^{2,3}
- Backed by extensive experience and commitment from Fresenius Kabi
 - Oncology medication supplier for over 25 years in the United States⁴
 - The largest injectable oncology portfolio in the United States⁴
- Collaborative support through the KabiCare[™] Patient Support Program



As little as \$0 copay for eligible* patients prescribed STIMUFEND[®]

*Eligibility criteria apply. Patients are not eligible for commercial copay support if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.

Important Safety Information (cont'd)

Acute Respiratory Distress Syndrome (ARDS)

- ARDS can occur in patients receiving pegfilgrastim products
- Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Stimufend
- Discontinue Stimufend in patients with ARDS



Stimufend[®]
pegfilgrastim-fpgk

Numerous biosimilar options present difficult choices for decision-makers⁵⁻⁷

Navigating the needs of various decision-makers can complicate G-CSF biosimilar selection⁵⁻⁷




Important Safety Information (cont'd)

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
- The majority of reported events occurred upon initial exposure and can recur within days after the discontinuation of initial anti-allergic treatment
- Permanently discontinue Stimufend in patients with serious allergic reactions

Please see additional Important Safety Information on pages 18-19 and accompanying Full Prescribing Information.



Selecting the right biosimilar depends on⁵⁻⁷

- Access and reimbursement
- Product quality
- Supply reliability
- Service support solutions
- Manufacturing capabilities



With a complex biosimilar landscape, decision-makers require continued support to find more affordable treatment options^{6,8}

Important Safety Information (cont'd)


Use in Patients with Sickle Cell Disorders

- In patients with sickle cell trait or disease, severe and sometimes fatal sickle cell crises can occur in patients receiving pegfilgrastim products
- Discontinue Stimufend if sickle cell crisis occurs

STIMUFEND® (pegfilgrastim-fpgk): Established biosimilarity to Neulasta® (pegfilgrastim)

Proven structural, functional, and clinical similarity^{2,3}

STIMUFEND® is FDA approved based on the totality of evidence supporting its biosimilarity to Neulasta®.




Important Safety Information (cont'd)

Glomerulonephritis

- Has occurred in patients receiving pegfilgrastim products
- Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
- Generally, events resolved after dose-reduction or discontinuation of pegfilgrastim products
- If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Stimufend

Please see additional Important Safety Information on pages 18-19 and accompanying Full Prescribing Information.



Clinical biosimilarity

- Confirmed bioequivalence to Neulasta^{®2}
- Similar immunogenicity to Neulasta^{®3}
- Highly similar safety and tolerability profile^{2,3}



The biosimilarity of STIMUFEND[®] and Neulasta[®] were established using an extensive range of rigorous analytical techniques^{2,3}


Important Safety Information (cont'd)

Leukocytosis


- Increased white blood cell counts of $100 \times 10^9/L$ have been observed
- Monitoring of complete blood count (CBC) during Stimufend therapy is recommended

Confirmed bioequivalence to Neulasta® (pegfilgrastim)² and similar immunogenicity³

Phase I PK/PD trial²




Arithmetic mean (SD) pegfilgrastim serum concentration time profiles after a single dose of pegfilgrastim in healthy subjects.




Arithmetic mean (SD) observed ANC-time profiles after a single dose of pegfilgrastim in healthy subjects.

- STIMUFEND® (pegfilgrastim-fpgk) was assessed in healthy subjects in a double-blind, randomized, 2-sequence, 2-period, 2-treatment, crossover Phase I study (NCT03251248)²
- 240 subjects received both treatments and were included in the PK/PD analysis sets
- Primary PK endpoints were AUC from time zero to the last sampling time, AUC from time zero extrapolated to infinity, and C_{max}. Primary PD endpoints were E_{max} and AUE from time zero (pre-dose) to time to last quantifiable concentration for ANC
- For all primary PK/PD parameters, the 90% repeated confidence intervals of the geometric means ratio of STIMUFEND® to Neulasta® were entirely within the equivalence range (80%-125%), confirming bioequivalence²

Please see additional Important Safety Information on pages 18-19 and accompanying Full Prescribing Information.



Phase I immunogenicity trial³



- STIMUFEND® demonstrated noninferior immunogenicity to Neulasta® with confirmed ADA positive rates of 8.9% and 9.5% respectively
- The immunogenicity and safety profiles of STIMUFEND® were demonstrated in healthy subjects in a double-blind, randomized, parallel-group, Phase I study (NCT03251339)³
- A total of 336 subjects were randomized and treated
- Primary endpoints were confirmed treatment-induced ADA-positive status and confirmed NAb status to pegfilgrastim from pre-dose until the end of study
- No filgrastim-specific neutralizing antibodies were detected in either group

ADA, antidrug antibody; ANC, absolute neutrophil count; AUC, area under the curve; AUE, area under the effect-time curve; CI, confidence interval; C_{max}, maximum concentration; E_{max}, maximum observed effect; NAb, neutralizing antibody; PD, pharmacodynamic; SD, standard deviation.

Important Safety Information (cont'd)

Thrombocytopenia

- Thrombocytopenia has been reported in patients receiving pegfilgrastim products. Monitor platelet counts



Highly similar safety and tolerability profile^{2,3}

Phase I PK/PD trial²

Most common TEAEs (>5% of subjects)

	STIMUFEND® (pegfilgrastim-fpgk) (N=270) n (%)	Neulasta® (pegfilgrastim) (N=266) n (%)
Headache	151 (55.9)	150 (56.4)
Musculoskeletal pain	133 (49.3)	114 (42.9)
Bone pain	67 (24.8)	70 (26.3)
Back pain	45 (16.7)	55 (20.7)
Upper respiratory tract infection	32 (11.9)	20 (7.5)
Nausea	30 (11.1)	31 (11.7)
Injection-site pain	28 (10.4)	25 (9.4)
Myalgia	27 (10.0)	23 (8.6)
Neutropenia	24 (8.9)	22 (8.3)
Abdominal pain	23 (8.5)	21 (7.9)
Palpitations	23 (8.5)	14 (5.3)
Injection-site bruising	17 (6.3)	18 (6.8)
Abdominal pain upper	13 (4.8)	19 (7.1)
Leukocytosis	13 (4.8)	14 (5.3)

- Adverse events with STIMUFEND® were consistent with the administration of Neulasta®²
- TEAEs were generally mild to moderate in severity and were self limiting²
- Clinically significant splenomegaly* (Grade 1 or 2): STIMUFEND® (n=3); all resolved spontaneously with no further study drug administered²

TEAE, treatment-emergent adverse event.


*Rare cases of splenic rupture have been reported following administration of filgrastim or pegfilgrastim; therefore, the spleen was monitored throughout the study.

Important Safety Information (cont'd)

Capillary Leak Syndrome (CLS)

- CLS has been reported after G-CSF administration, including pegfilgrastim products

Please see additional Important Safety Information on pages 18-19 and accompanying Full Prescribing Information.



Phase I immunogenicity trial³

Most common TEAEs (>5% of subjects)

	STIMUFEND® (pegfilgrastim-fpgk) (N=168) n (%)	Neulasta® (pegfilgrastim) (N=168) n (%)
Headache	105 (62.5)	120 (71.4)
Bone pain	113 (67.3)	101 (60.1)
Spinal pain	67 (39.9)	68 (40.5)
Upper respiratory tract infection	32 (19.0)	20 (11.9)
Nausea	32 (19.0)	19 (11.3)
White blood cell count increased [†]	23 (13.7)	27 (16.1)
Myalgia	19 (11.3)	17 (10.1)
Vomiting	18 (10.7)	9 (5.4)
Musculoskeletal chest pain	12 (7.1)	17 (10.1)
Abdominal pain	9 (5.4)	15 (8.9)
Diarrhea	8 (4.8)	15 (8.9)
Oropharyngeal pain	12 (7.1)	14 (8.3)
Injection-site bruising	12 (7.1)	10 (6.0)
Arthralgia	11 (6.5)	11 (6.5)
Dizziness	11 (6.5)	11 (6.5)
Contusion	11 (6.5)	7 (4.2)
Fatigue	7 (4.2)	11 (6.5)
Back pain	8 (4.8)	9 (5.4)

- TEAEs were generally mild to moderate in severity, were self-limiting, and resolved without sequelae³
- Both instances of splenomegaly (Grades 1 and 2, respectively), resolved spontaneously and the subjects completed the study³

[†]All events considered related to study drug.

Important Safety Information (cont'd)

Capillary Leak Syndrome (cont'd)

- Characterized by hypotension, hypoalbuminemia, edema and hemoconcentration
- Episodes vary in frequency, severity and may be life-threatening if treatment is delayed
- Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care



Offering convenience and confidence by design

Convenient dosing, administration, and storage of STIMUFEND® (pegfilgrastim-fpgk)¹

- Only 1 injection per chemotherapy cycle
- Single-dose, pre-filled syringe delivers 6-mg/0.6-mL solution for subcutaneous injection
- Storage up to 72 hours at room temperature, 68°F to 77°F (20°C to 25°C)*
- 36-month shelf life



*STIMUFEND® must be refrigerated. STIMUFEND® that is left at room temperature for more than 72 hours must be discarded.

Important Safety Information (cont'd)

Potential for Tumor Growth Stimulatory Effects on Malignant Cells


- G-CSF receptor has been found on tumor cell lines
- The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.

Please see additional Important Safety Information on pages 18-19 and accompanying Full Prescribing Information.



STIMUFEND® single-dose syringe¹

- Pre-filled syringe with a 27-gauge needle
- Fully passive safety device
- Automatic activation needle guard
- Designed for home and clinical use



For illustration purposes only.



With STIMUFEND®, Fresenius Kabi is committed to ongoing device innovation, making the delivery process convenient and comfortable

Important Safety Information (cont'd)

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer

- MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

* The needle cap contains dry natural rubber (derived from latex).

Fresenius Kabi provides comprehensive patient support

We are dedicated to providing your patients with ongoing support to help them access Fresenius Kabi medications as prescribed



Centralized patient support portal with real-time status*



Dedicated support to address access challenges



Financial support, with as little as \$0 copay for commercially insured patients prescribed STIMUFEND® (pegfilgrastim-fpgk)[†]



Patients may be eligible for assistance through the Fresenius Kabi Patient Assistance Program (PAP)[‡] or through an independent nonprofit PAP[§]



Bridge to Therapy program to avoid treatment delay[†]



Educational resources for patients




Identifying potential treatment-related transportation and lodging resources[§]

* In case of medical benefit; otherwise, real-time status available up to prescription transfer to dispensing pharmacy.

[†] Eligibility criteria apply. Patients are not eligible for commercial copay assistance or Bridge to Therapy program support if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.

[‡] Government insurance or uninsured/underinsured patients may be eligible. Underinsured means that your patient's health insurance plan does not cover STIMUFEND®.

[§] Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits' criteria. Fresenius Kabi has no control over these programs.



KabiCare™ provides additional support programs to eligible patients under various insurance plans*

- Commercial or private insurance[†]
- Government insurance (Medicare/Medicaid)[‡]
- Uninsured/Underinsured[§]



Patient Support Program by Fresenius Kabi



Enroll Online

Visit CoverMyMeds.com

To learn more, please visit kabicare.us
or call 1.833.KABICARE (1-833-522-4227)

Important Safety Information (cont'd)

Aortitis

- Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy
- Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count)
- Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Stimufend if aortitis is suspected



A proud heritage of manufacturing and supply reliability

We are committed to addressing the needs of the oncology decision-makers with⁴:

Over **25** years of experience supplying oncology medications in the United States

Over **30 products** used in more than **460** different chemotherapy regimens

One of the largest injectable oncology portfolios in the industry, with:

82% of products filled and finished in the United States

Over **220 chemotherapy regimens** that can be supported entirely by Fresenius Kabi



STIMUFEND® (pegfilgrastim-fpgk) demonstrates our commitment to providing high-quality products and making biologic treatments a more affordable option

Important Safety Information (cont'd)


Nuclear Imaging

- Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results

Most common adverse reactions


- Bone pain
- Pain in extremity

Please see additional Important Safety Information on pages 18-19 and accompanying Full Prescribing Information.



Fresenius Kabi is committed to launching multiple biosimilars in oncology and immunology in the United States

Focused expertise in biosimilar therapies



Fresenius Kabi is committed to providing valued biologic treatments through the development of new immunology and oncology pipeline therapies in our expanding biosimilars portfolio



Important Safety Information

Indications and Usage

Stimufend is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Stimufend is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Limitations of Use

Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Contraindication

- Stimufend (pegfilgrastim-fpgk) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
- Reactions have included anaphylaxis

Splenic Rupture

- Splenic rupture, including fatal cases, can occur following the administration of pegfilgrastim products
- Evaluate for an enlarged spleen or splenic rupture in patients who report left upper abdominal or shoulder pain

Acute Respiratory Distress Syndrome (ARDS)

- ARDS can occur in patients receiving pegfilgrastim products
- Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving Stimufend
- Discontinue Stimufend in patients with ARDS

Serious Allergic Reactions

- Serious allergic reactions, including anaphylaxis, can occur in patients receiving pegfilgrastim products
- The majority of reported events occurred upon initial exposure and can recur within days after the discontinuation of initial anti-allergic treatment
- Permanently discontinue Stimufend in patients with serious allergic reactions

Use in Patients with Sickle Cell Disorders

- In patients with sickle cell trait or disease, severe and sometimes fatal sickle cell crises can occur in patients receiving pegfilgrastim products
- Discontinue Stimufend if sickle cell crisis occurs

Glomerulonephritis

- Has occurred in patients receiving pegfilgrastim products
- Diagnoses based on azotemia, hematuria, proteinuria, and renal biopsy
- Generally, events resolved after dose-reduction or discontinuation of pegfilgrastim products
- If suspected, evaluate for cause and if cause is likely, consider dose-reduction or interruption of Stimufend

Leukocytosis

- Increased white blood cell counts of $100 \times 10^9/L$ have been observed
- Monitoring of complete blood count (CBC) during Stimufend therapy is recommended

Thrombocytopenia

- Thrombocytopenia has been reported in patients receiving pegfilgrastim products. Monitor platelet counts

Capillary Leak Syndrome (CLS)

- CLS has been reported after G-CSF administration, including pegfilgrastim products
- Characterized by hypotension, hypoalbuminemia, edema and hemoconcentration
- Episodes vary in frequency, severity and may be life-threatening if treatment is delayed
- Patients with symptoms should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care

Potential for Tumor Growth Stimulatory Effects on Malignant Cells

- G-CSF receptor has been found on tumor cell lines
- The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded.

Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer

- MDS and AML have been associated with the use of pegfilgrastim products in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings.

Aortitis

- Aortitis has been reported in patients receiving pegfilgrastim products. It may occur as early as the first week after start of therapy
- Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count)
- Consider aortitis in patients who develop these signs and symptoms without known etiology. Discontinue Stimufend if aortitis is suspected

Nuclear Imaging

- Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone imaging results

Most common adverse reactions

- Bone pain
- Pain in extremity

Please see Stimufend full Prescribing Information.

Stimufend Injection: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only.



Stimufend[®]
pegfilgrastim-fpgk

**Similar where it counts.
Different where it matters.**

**Simplify the complex biosimilar
landscape with STIMUFEND[®]**

- Clinically proven biosimilarity to Neulasta[®] (pegfilgrastim)^{2,3}
- Extensive oncology experience and commitment from Fresenius Kabi⁴
- Collaborative patient support program

Important Safety Information

Indications and Usage

Stimufend is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Stimufend is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Limitations of Use

Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.


Contraindication

- Stimufend (pegfilgrastim-fpgk) is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products
- Reactions have included anaphylaxis

References: 1. STIMUFEND[®] (pegfilgrastim-fpgk). Full Prescribing Information. Fresenius Kabi USA, LLC; 2023. 2. Lickliter J, Kanceva R, Vincent E, et al. Pharmacokinetics and pharmacodynamics of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta[®] in healthy subjects: a randomized, double-blind trial. *Clin Ther*. 2020;42(8):1508-1518.e1. doi:10.1016/j.clinthera.2020.05.020 3. Wynne C, Schwabe C, Vincent E, et al. Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta[®] in healthy subjects: a randomized, double-blind trial. *Pharmacol Res Perspect*. 2020;8(2):e00578. doi:10.1002/prp2.578 4. Data on file. Fresenius Kabi USA, LLC. 5. Cazap E, Jacobs I, McBride A, Popovian R, Sikora K. Global acceptance of biosimilars: importance of regulatory consistency, education, and trust. *Oncologist*. 2018;23(10):1188-1198. doi:10.1634/theoncologist.2017-0671 6. Tinsley SM, Grande C, Olson K, Plato L, Jacobs I. Potential of biosimilars to increase access to biologics: considerations for advanced practice providers in oncology. *J Adv Pract Oncol*. 2018;9(7):699-716. 7. Khraishi M, Stead D, Lukas M, Scotte F, Schmid H. Biosimilars: a multidisciplinary perspective. *Clin Ther*. 2016;38(5):1238-1249. doi:10.1016/j.clinthera.2016.02.023 8. Patel KB, Arantes LH Jr, Tang WY, Fung S. The role of biosimilars in value-based oncology care. *Cancer Manag Res*. 2018;10:4591-4602. doi:10.2147/CMAR.S164201

**Please see additional Important Safety Information on pages 18-19
and accompanying full Prescribing Information.**

©2024 Fresenius Kabi USA, LLC. All Rights Reserved. STIMUFEND and KABICARE are registered trademarks of Fresenius Kabi. 2316-STIM-02-10/22 v2.0



**Learn more:
Scan the QR code
or visit
STIMUFENDHCP.com**



**FRESENIUS
KABI**